Skip to main content

UTHR United Therapeutics Corporation

Healthcare

598.72 Close 10/30
Since 2024-12-02 +61.8%
Open
600.00
High
609.99
Low
593.57
Prev close
593.54
Volume
500.9K
Amplitude
2.77%
P/E
21.5
P/B
4.0
Revenue YoY (TTM)
+2.5%
52W 430.02 609.99

Is United Therapeutics Corporation a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Strong, Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Pricey.
TTM P/E 21.45 56th percentile Pricey
Price / book 4.01 78th percentile Pricey
Free-cash-flow yield (%) 4.26 64th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Strong All 3 indicators are Top.
ROE, TTM (%) 20.48 83th percentile Top
Operating margin, TTM (%) 44.46 90th percentile Top
FCF margin, TTM (%) 34.65 88th percentile Top
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral Diluted EPS growth, TTM YoY is Good, but Revenue growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 2.49 42th percentile Average
Diluted EPS growth, TTM YoY (%) 8.94 60th percentile Good
Momentum Strong 60-day return is Top; 240-day return is Good.
60-day return (%) 12.34 87th percentile Top
240-day return (%) 28.37 77th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 361,390,149 96th percentile Top
60-day annualized volatility (%) 38.98 45th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

United Therapeutics Corporation (UTHR) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From United Therapeutics Corporation to every stock like it

AI finds several complementary traits of United Therapeutics Corporation across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like United Therapeutics Corporation

United Therapeutics Corporation (UTHR) peers and tracking

Watchlist

This page refreshes daily after the close. Add United Therapeutics Corporation to your watchlist to track signal changes on your next visit.

United Therapeutics Corporation (UTHR) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

21 historical occurrences (since 2017-01-04)

Average forward return after 52-week adjusted-price high

20-day: Win 60%, Sample 20, Median +3.04%, Excess +0.69%, Beat mkt rate 60%

60-day: Win 55%, Sample 20, Median +2.77%, Excess -2.37%, Beat mkt rate 40%

120-day: Win 65%, Sample 20, Median +9.8%, Excess +3.7%, Beat mkt rate 50%

120 days after: historical avg +9.45%

20-day +2.04%
60-day +3.06%
120-day +9.45%
20-day
60-day
120-day
Win
60%
55%
65%
Sample
20
20
20
Median
+3.04%
+2.77%
+9.8%
Excess
+0.69%
-2.37%
+3.7%
Beat mkt rate
60%
40%
50%

Over 20 occurrences, 120-day forward avg gained 9.45%, beat the market by 3.7 pts; win rate 65%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 0Insufficient data
20-40 178+69.9% +73% 100% +50.4%
40-60 252+37.2% +41.8% 98% +14.8%
60-80 412+10.1% +7.3% 64.3% -3.3%
80-100 You are here355+13.1% +13.8% 76.3% +15.1%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 21.45, placing it in the 99.2 own-history percentile, inside the 80-100 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
Insufficient data
(14d)
+24.2%
Win rate 84.9% Excess +12.6%
185d
Now
+2.3%
Win rate 52.3% Excess -1.8%
619d
60-day momentum down
+59.1%
Win rate 100% Excess +43.3%
51d
+19.5%
Win rate 82% Excess +8.8%
256d
+8.3%
Win rate 74.5% Excess +9.9%
192d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 619 historical days, 120-day forward avg gained 2.3%, win rate 52.3%, lagged the market by 1.8%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

16 times historically; 60-day forward avg -1.58%, win rate 50%, beating the market by -3.79 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

9 times historically; 60-day forward avg +5.59%, win rate 44.4%, beating the market by +2.34 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

25 times historically; 60-day forward avg +3.77%, win rate 68.2%, beating the market by -1.33 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.